From: Factors associated with the 6-minute walk distance in patients with systemic sclerosis

N
| Value | ||
---|---|---|---|

Demographic data | |||

Females, n (%)
| 298 | 242 | (81.2) |

Age at inclusion (years), mean (SD) | 298 | 58.2 | (13.3) |

BMI (kg/m^{2}), mean (SD)
| 283 | 24.9 | (5.3) |

Smoking history, n (%)
| 297 | 119 | (40.1) |

Diagnosis of SSc | |||

SSc subtype | |||

lcSSc, n (%)
| 298 | 245 | (82.2) |

dcSSc, n (%)
| 298 | 53 | (17.8) |

Disease duration at inclusion | |||

Since diagnosis (years), mean (SD) | 298 | 9.1 | (8.1) |

Since first non-Raynaud symptom (years), mean (SD) | 244 | 9.9 | (8.5) |

Since Raynaud phenomenon onset (years), mean (SD) | 279 | 15.6 | (12.2) |

Immunological profile | |||

Anti-centromere antibodies, n (%)
| 291 | 163 | (56.0) |

Anti-topoisomerase I antibodies, n (%)
| 291 | 57 | (19.6) |

Anti-RNA polymerase III antibodies, n (%)
| 291 | 7 | (2.4) |

Anti-RNP antibodies, n (%)
| 291 | 15 | (5.2) |

Nailfold capillaroscopy | |||

Specific organic microangiopathy, n (%)
| 109 | 98 | (89.9) |

History of organ involvement | |||

Interstitial lung disease | |||

No ILD, n (%)
| 270 | 159 | (58.9) |

Limited ILD, n (%)
| 270 | 82 | (30.4) |

Extensive ILD, n (%)
| 270 | 29 | (10.7) |

Pulmonary arterial hypertension, n (%)
| 286 | 17 | (5.9) |

Scleroderma renal crisis, n (%)
| 285 | 1 | (0.4) |

Digital ulcers (previously or at inclusion), n (%)
| 298 | 128 | (43.0) |

Acute venous thrombosis, n (%)
| 297 | 33 | (11.1) |

Acute arterial thrombosis, n (%)
| 297 | 39 | (13.1) |

Chronic cardiovascular disease, n (%)
| 296 | 21 | (7.1) |

Clinical evaluation at inclusion | |||

Modified Rodnan skin score, mean (SD) | 297 | 4.96 | (5.95) |

Telangiectasia, n (%)
| 275 | 199 | (72.4) |

NYHA functional class | |||

Class I, n (%)
| 296 | 132 | (44.6) |

Class II, n (%)
| 296 | 101 | (34.1) |

Class III, n (%)
| 296 | 57 | (19.3) |

Class IV, n (%)
| 296 | 6 | (2.0) |

Cardiovascular symptoms, n (%)
| 298 | 24 | (8.1) |

Joint symptoms, n (%)
| 296 | 125 | (42.2) |

Muscle symptoms, n (%)
| 297 | 57 | (19.2) |

6-minute walk test | |||

Total distance (m), mean (SD) | 298 | 438.3 | (108.1) |

Total distance (% predicted), mean (SD) | 290 | 81.6 | (17.8) |

Initial SpO_{2} (%), mean (SD)
| 280 | 98.1 | (2.1) |

Final SpO_{2} (%), mean (SD)
| 275 | 97.5 | (3.3) |

ΔSpO_{2} (%), mean (SD)
| 276 | -0.58 | (2.72) |

Initial Borg score, mean (SD) | 294 | 0.4 | (1.1) |

Final Borg score, mean (SD) | 294 | 2.5 | (2.2) |

ΔBorg score, mean (SD) | 293 | 2.1 | (1.9) |

Initial sBP (mmHg), mean (SD) | 292 | 123.8 | (16.6) |

Final sBP (mmHg), mean (SD) | 292 | 132.9 | (18.2) |

ΔsBP (mmHg), mean (SD) | 291 | 9.2 | (14.0) |

Initial dBP (mmHg), mean (SD) | 271 | 97.4 | (3.4) |

Final dBP (mmHg), mean (SD) | 292 | 73.6 | (10.0) |

ΔdBP (mmHg), mean (SD) | 291 | 0.95 | (10.2) |

Initial HR (bpm), mean (SD) | 289 | 76.7 | (12.3) |

Final HR (bpm), mean (SD) | 288 | 87.1 | (15.9) |

ΔHR (bpm), mean (SD) | 288 | 10.4 | (11.2) |

Biological data | |||

Hemoglobin (g/dl), mean (SD) | 291 | 13.4 | (1.4) |

ESR (mm/h), mean (SD) | 258 | 14.8 | (15.3) |

CRP (mg/L), mean (SD) | 293 | 4.0 | (4.7) |

Creatinin (mg/L), mean (SD) | 294 | 8.0 | (2.8) |

Estimated GFR (ml/min/1.73 m^{2}), mean (SD)
| 294 | 89.1 | (21.5) |

Elevated Nt-pro-BNP, n (%)
| 290 | 43 | (14.8) |

CK (IU), mean (SD) | 289 | 93 | (59.5) |

Ferritin (ng/ml), mean (SD) | 268 | 105.5 | (136.4) |

Complement activation, n (%)
| 265 | 9 | (3.4) |

Transthoracic echocardiography | |||

Left ventricular ejection fraction (%), mean (SD) | 250 | 62.8 | (6.7) |

Left ventricular diastolic dysfunction, n (%)
| 229 | 124 | (54.2) |

Valvular heart disease, n (%)
| 244 | 41 | (16.8) |

Peak TRV (m/s), mean (SD) | 98 | 2.62 | (0.54) |

RA–RV pressure gradient (mmHg), mean (SD) | 206 | 27.4 | (13.4) |

Estimated sPAP (mmHg), mean (SD) | 194 | 31.5 | (13.1) |

RA area (cm^{2}), mean (SD)
| 139 | 15.0 | (4.6) |

IVC dilation and/or decreased IVC collapse, n (%)
| 210 | 16 | (7.6) |

Pericardial effusion, n (%)
| 230 | 5 | (2.2) |

Pulmonary function tests | |||

TLC (% predicted), mean (SD) | 276 | 96.2 | (16.4) |

FVC (% predicted), mean (SD) | 287 | 103.5 | (21.8) |

FEV1 (% predicted), mean (SD) | 286 | 95.1 | (21.8) |

FEV1/FVC (%), mean (SD) | 286 | 79.2 | (10.7) |

DLCO (% predicted), mean (SD) | 285 | 70.0 | (19.7) |

KCO (% predicted), mean (SD) | 278 | 80.9 | (17.6) |

Composite scores | |||

EScSG-AI score, mean (SD) | 289 | 1.16 | (1.2) |

Medsger severity score, mean (SD) | 228 | 4.17 | (2.5) |

HAQ-DI score, mean (SD) | 223 | 0.61 | (0.7) |

Treatments | |||

Negative chronotropic drugs, n (%)
| 293 | 87 | (29.7) |

Positive chronotropic drugs, n (%)
| 293 | 10 | (3.4) |